← All Xtl Biopharmaceuticals LTD filings

Xtl Biopharmaceuticals LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
XTLB
Xtl Biopharmaceuticals LTD
20-F: XTL Biopharmaceuticals Shifts Focus to Psychedelics
XTL Biopharmaceuticals Ltd. has filed its annual report on Form 20-F, detailing its financial performance and strategic shifts, including the acquisition of Psyga Bio Ltd. and the ongoing challenges with The Social Proxy Ltd.
NASDAQ
XTLB
Xtl Biopharmaceuticals LTD
20-F: XTL Biopharmaceuticals Expands into AI Data Collection with Social Proxy Acquisition; Reports FY24 Results
XTL Biopharmaceuticals diversifies its business by acquiring The Social Proxy, an AI web data company, while reporting a net loss for the fiscal year ended December 31, 2024.
NASDAQ
XTLB
Xtl Biopharmaceuticals LTD
20-F: XTL Biopharmaceuticals Reports Financial Results for Fiscal Year 2023, Outlines Strategic Shift Towards AI
XTL Biopharmaceuticals reports a net loss for 2023 and announces a strategic shift by entering into a term sheet to acquire The Social Proxy, an AI web data company.